EVOTEC SE
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec and Related Sciences enter integrated drug discovery and development partnership
2021-02-09 / 07:30
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
. PARTNERSHIP COMBINES RELATED SCIENCES' COLLABORATIVE SCIENCE MODEL AND DATA-DRIVEN APPROACH TO IDENTIFYING
BIOLOGICAL BREAKTHROUGHS WITH EVOTEC'S INTEGRATED PLATFORM TO DRIVE INNOVATIVE MULTIMODALITY DRUG DISCOVERY FROM
TARGET TO CLINIC
. EVOTEC WILL BENEFIT FROM SUCCESS THROUGH MILESTONES, ROYALTIES AND FOUNDING EQUITY STAKES IN ALL RELATED SCIENCES
ASSETS DEVELOPED WITHIN THIS COLLABORATION
Hamburg, Germany, 09 February 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered
into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to
generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.
Leveraging their complementary strengths, Evotec and Related Sciences will jointly discover and develop a multitude of
therapeutic approaches for clearly defined patient populations with significant unmet medical needs. Related Sciences
integrates data-driven identification of promising new therapeutic opportunities for patients with a unique
team-science model that assembles field leaders from around the world to de-risk and advance the creation of valuable
new medicines in breakthrough areas of biology. By partnering with Evotec, Related Sciences will benefit from Evotec's
significant track record of success, computational capabilities, and disease area know-how in drug discovery and
development. Evotec will leverage its comprehensive proprietary platform of integrated discovery and development
services to progress the joint programmes from target to the clinic, informing drug intervention strategies, supporting
target prioritisation and target validation, and generating hits, leads, candidates, and biomarkers.
In addition to substantial investment from Related Sciences and its companies to support Evotec-led research and
discovery efforts across portfolios of promising new drug programmes, Evotec will be eligible to receive milestones,
royalties, and a founding equity stake in all Related Sciences assets developed under the partnership.
Dr Craig Johnstone, Chief Operating Officer of Evotec, said: "We are delighted to enter into this unique and
transformative partnership with Related Sciences. Through the integration of best-in-class science, human data-driven
target selection, project leadership, and portfolio management, the combined expertise of Evotec and Related Sciences
will generate novel, high-quality therapeutics, leading to treatments for patients with significant medical needs."
Dr Jack Milwid, Managing Partner and Head of Research at Related Sciences, said: "Our platform at Related Sciences
integrates insights from data and field-leading scientists to answer the question 'where can major new therapeutic
advances be achieved for patients in need?' Evotec's world-class, multimodality, integrated discovery and computational
capabilities significantly empowers our efforts to uncover new, best-in-class medicines for poorly served patient
populations."
No financial details of the collaboration were disclosed.
ABOUT RELATED SCIENCES
Related Sciences (RS) is a data-driven venture creation firm founded to discover new medicines for diseases with major
unmet needs. RS assembles portfolios of promising therapeutic programs in breakthrough areas of biology led by
distributed teams of field-leading scientists and clinicians from around the world. By integrating a range of data,
scientific, drug discovery, and business model innovations, RS seeks to create medicines that have the greatest
possible chances of working safely and effectively in patients within a virtual operating model that reduces costs,
attrition risk, and geographic constraints, to maximize potential value creation. RS was founded by a team with deep
expertise in life sciences company creation, investment strategy, and data science, and is backed by a luminary group
of investors.
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and
venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us
on Twitter @Evotec.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any such statement is based.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255,
gabriele.hansen@evotec.com
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com
=----------------------------------------------------------------------------------------------------------------------
2021-02-09 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf,
Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1166904
End of News DGAP News Service
=------------ 1166904 2021-02-09
(END) Dow Jones Newswires
February 09, 2021 01:32 ET (06:32 GMT)
